P278 Feasibility study of adjuvant fluorouracil/epirubicin/cyclophosphamide (FEC 100) followed by triweekly docetaxel (D) plus trastuzumab (H) in HER2/neu positive early breast cancer
Titel:
P278 Feasibility study of adjuvant fluorouracil/epirubicin/cyclophosphamide (FEC 100) followed by triweekly docetaxel (D) plus trastuzumab (H) in HER2/neu positive early breast cancer
Auteur:
Tanaka, M. Anan, K. Umeda, S. Yamaguchi, M. Sasaki, H. Rai, Y. Ohno, S. Toh, U. Tamura, K. Mitsuyama, S.